ReproCELL Incorporated
Everything filed on one company: the documents, the statements, the register, the board, the buyback and the property table — each figure as filed, with the report it came from.
Filings
Financials
Ownership
Governance
Capital Returns
Assets
Latest values as text and table
ReproCELL Incorporated
ReproCELL Incorporated (株式会社リプロセル, 4978), Chemicals. 1 cross-shareholding, a board of 6 and 10 largest shareholders, as filed on EDINET for the year to March 2026. EDINET filing S100YLVF, filed 2026-06-26. Source: company filings on EDINET (Financial Services Agency of Japan).
Financial summary
| Fiscal year end | Revenue (¥bn) | Profit (¥bn) | Total assets (¥bn) | EPS (¥) | DPS (¥) | Employees |
|---|---|---|---|---|---|---|
| 2022-03-31 | 2.2 | −0.6 | 8.1 | −7.57 | — | 98 |
| 2023-03-31 | 3.0 | −0.3 | 8.4 | −3.62 | — | 92 |
| 2024-03-31 | 2.4 | −0.0 | 9.1 | −0.37 | — | 96 |
| 2025-03-31 | 3.0 | 0.1 | 9.7 | 1.11 | — | 99 |
| 2026-03-31 | 2.2 | −0.6 | 9.7 | −6.25 | — | 101 |
Source: company filings on EDINET (Financial Services Agency of Japan). · JSON
Cross-shareholdings
| Company held | Shares | Book value (¥bn) | % of shares outstanding |
|---|---|---|---|
| Ｋｒｉｎｇｌｅ Ｐｈａｒｍａ， Ｉｎｃ． | 100,000 | 0.0 | 1.4 |
% of shares outstanding: shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end
Source: company filings on EDINET (Financial Services Agency of Japan). · JSON · Markdown